Nanoemulsion Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| CAGR | 7.20 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Nanoemulsion Market Analysis
The nanoemulsion market is expected to register a CAGR of nearly 7.2% during the forecast period (2022-2027).
The COVID-19 outbreak is expected to have a positive effect on the market for nanoemulsions. Nanoemulsions are used extensively as vaccine carriers and adjuvants. In vaccine development, nanoemulsions are used as they offer various advantages like increasing the surface area of an antigen allowing for favorable antigen presentation, slow release of the antigen, and uniform dispersion, and good stability of the vaccine. In a research article appearing in the September 2020 issue of News-Medical.Net, researchers stated that a potential COVID-19 vaccine can include a cationic nanoemulsion-based system. These nanoemulsion systems can produce immune responses that are similar to live attenuated vaccines but do not run the risk of reversion. moreover, as per a research article 'Emerging trends and promises of nanoemulsions in therapeutics of infectious diseases' published in May 2022, revealed that nanoemulsions and their modified forms have been successfully employed for the delivery of antimicrobials to treat infectious disease. These nanoemulsion-based formulation systems are shifting the paradigm for therapeutics and diagnosis of infectious diseases. These developments are likely to affect the market in a positive manner.
The studied market growth can largely be attributed to factors such as the increasing burden of chronic diseases and development of vaccines, rising adoption of targeted therapeutics and image-guided therapies, and the high stability and chemical properties for efficient drug delivery.
Vaccines play a significant role in the treatment of several chronic and infectious diseases, which gained more prevalence in recent decades. An increasing number of biopharmaceutical companies are using nanoemulsion formulations in the development of vaccines. Moreover, companies, such as BlueWillow Biologics Inc., a nanotechnology-based vaccine manufacturer, received a United States patent for an intranasal NanoVax anthrax vaccine. The NanoVax nanoemulsion platform could elicit both a systemic and mucosal response when administered intranasally. This was in contrast with other conventional vaccines are injected (intramuscular) and fail to provide mucosal immunity. The NanoVax platform has also been used to develop vaccines against two strains of genital herpes viruses, HSV1 and HSV2.
The last decade showed several promises, with successful results of nanoemulsion being used as adjuvants for vaccines to treat chronic infections and cancer diseases through targeted therapies. Increasing research projects through institutes, in collaboration with various government funds and companies, are being witnessed, which primarily deal with the improvement of the oral delivery of drugs for the management of chronic diseases. Nanoemulsion provides enhanced transdermal permeation of drugs, which increases the plasma concentration profiles and bioavailability of the drug. In the case of cancer indications, the nanoemulsion and nanoparticle form offers a higher potential of killing the cancer cells, as well as better treatment of cancer, osteoarthritis, and fibromyalgia, among others. With the constant demand for new and improved vaccines, nanoemulsion applications are expected to increase globally and drive the market.
Nanoemulsion Market Trends
This section covers the major market trends shaping the Nanoemulsion Market according to our research experts:
The Antibiotics Segment is Expected to Register a Healthy CAGR Over the Forecast Period
Nanoemulsion formulations are becoming clinically useful as they can provide a substantial advantage over the conventional formulation of antibiotics. This is because the antibacterial activity of antibiotics can be enhanced significantly by dispensing them in a nanoparticle form. Nanoemulsions are used extensively in antibiotic drug deliveries and they have varied purposes. They can act as effective carriers for the bioactivation of antibiotics, helping their administration through various routes such as transdermal, topical, and oral delivery. There is a rising interest in the application of nanoemulsion in antimicrobial properties and effective anti-biofilm agents. This is expected to positively affect the market development during the forecast period.
There are various modes for the administration of nanoemulsion-based medicines. Oral and parenteral modes are quite popular, although other methods (for example, through eye droplets) are also popular. Companies operating in the market collaborate for novel product development. For example, In June 2020, Ascendia Pharmaceuticals announced that it was using its EmulSol technology for making a pipeline product called ASD-004, which is a clear emulsion cyclosporin eyedrop for dry eyes. Initiatives such as these are likely to boost the market growth over the coming years.
Rising antibiotic resistance has received increased attention from researchers and companies across the world. However, the rate of new antibiotics released in the market for therapeutic treatment against emerging 'superbugs' has been low. With increasing applications in a wide range of antibiotics for treating various diseases and the emergence of better treatment possibilities, the companies that invest in the antibiotics segment are steady. Thus, the success rate and adoption may further determine the growth of this market over the forecast period.
North America is Expected to Dominate the Market Over the Forecast Period
North America is expected to dominate the overall market during the forecast period due to the presence of key players, the high prevalence of chronic diseases in the region, and established healthcare infrastructure. Furthermore, beneficial government initiatives and an increase in the legalization of cannabis-based products are some of the factors expected to drive market growth. In this region, Canada is fast becoming a prominent player. The Canadian cannabis industry is one of the largest in the world. Nanoemulsions are being used by pharmaceutical drug manufacturers operating in this field. For instance, In June 2020, Emerald Health Therapeutics Inc. launched a new nanoemulsion-based Fast Action Spray product line involving cannabis infused with nanoemulsion. The innovative formulation offers unique advantages over existing formats of cannabis consumption in terms of convenience and predictability of consumption.
Furthermore, In February 2020, Pressure BioSciences Inc., a company based in Massachusetts, United States, announced the opening of its Ultra Shear Technology Demonstration Laboratory that can process CBD oil into high-quality, water-soluble nanoemulsions. The UST Demo Lab is located in the company's South Easton facility in Massachusetts. The UST Demo Lab will study ways to make hemp-derived cannabinoid oil effectively soluble in water and to optimize absorption and bioavailability when consumed or applied. Thus, innovative product developments by major companies in this region are expected to have a positive effect on the nanoemulsion market.
Nanoemulsion Industry Overview
The nanoemulsion market is moderately competitive and consists of a few major players and several small players. In terms of market share, the major players, namely, Ascendia Pharmaceuticals, Covaris Inc., Microfluidics (IDEX Corporation), Taiwan Liposome Company Ltd, and Allergan PLC, currently dominate the market.
Nanoemulsion Market Leaders
-
Covaris Inc.
-
Microfluidics (IDEX Corporation)
-
Allergan PLC
-
Ascendia Pharmaceuticals
-
Owen Biosciences, Inc
*Disclaimer: Major Players sorted in no particular order
Nanoemulsion Market News
- In September 2021, Oncology Pharma, Inc. received and segregated all funds necessary to execute the first phase of the development project of a nanoemulsion of dactinomycin.
- In August 2021, BlueWillow Biologics, Inc., a privately held clinical-stage biopharmaceutical company developing intranasal vaccines, announced positive interim results from the Phase 1 clinical trial of BW-1010, its next-generation intranasal anthrax vaccine candidate. BW-1010 combines BlueWillow's patented technology, a novel oil-in-water emulsion platform.
Nanoemulsion Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 High Stability and Chemical Properties for Efficient Drug Delivery
- 4.2.2 Increasing Burden of Chronic Diseases and Development of Vaccines
- 4.2.3 Rising Adoption of Targeted Therapeutics and Image-guided Therapies
-
4.3 Market Restraints
- 4.3.1 High Manufacturing Expenses and Technical Difficulties
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
-
5.1 By Application
- 5.1.1 Anesthetics
- 5.1.2 Antibiotics
- 5.1.3 Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
- 5.1.4 Immunosuppressants
- 5.1.5 Steroids
- 5.1.6 Other Applications
-
5.2 By Route of Administration
- 5.2.1 Oral
- 5.2.2 Parenteral
- 5.2.3 Other Routes of Administration
-
5.3 Geography
- 5.3.1 North America
- 5.3.1.1 United States
- 5.3.1.2 Canada
- 5.3.1.3 Mexico
- 5.3.2 Europe
- 5.3.2.1 Germany
- 5.3.2.2 United Kingdom
- 5.3.2.3 France
- 5.3.2.4 Italy
- 5.3.2.5 Spain
- 5.3.2.6 Rest of Europe
- 5.3.3 Asia-Pacific
- 5.3.3.1 China
- 5.3.3.2 Japan
- 5.3.3.3 India
- 5.3.3.4 Australia
- 5.3.3.5 South Korea
- 5.3.3.6 Rest of Asia-Pacific
- 5.3.4 Rest of the World
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 Allergan PLC
- 6.1.2 Ascendia Pharmaceuticals
- 6.1.3 Covaris Inc.
- 6.1.4 Foamix Pharmaceuticals
- 6.1.5 Latitude Pharmaceuticals Inc.
- 6.1.6 Microfluidics (IDEX Corporation)
- 6.1.7 Mitsubishi Tanabe Pharma
- 6.1.8 Santen Pharmaceutical Co. Ltd
- 6.1.9 Taiwan Liposome Company Ltd
- 6.1.10 Owen Biosciences Inc.
- 6.1.11 Latitude Pharmaceuticals Inc.
- 6.1.12 BlueWillow Biologics Inc.
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityNanoemulsion Industry Segmentation
Nanoemulsions are nano-sized emulsions, which are manufactured for improving the delivery of active pharmaceutical ingredients. With its unique properties, such as small droplet size, nanoemulsion makes an attractive option for application in the pharmaceutical industry. It significantly improves the bioavailability of hydrophobic drugs, where its market is primarily driven by its stability and chemical properties, increasing the adoption of targeted therapies and minimally invasive procedures. The Nanoemulsion Market is Segmented by Application (Anesthetics, Antibiotics, Nonsteroidal Anti-inflammatory Drugs (NSAIDs), Immunosuppressants, Steroids, and Other Applications), Route of Administration (Oral, Parenteral, and Other Routes of Administration), and Geography (North America, Europe, Asia-Pacific, and Rest of the World). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for all the above segments.
| By Application | Anesthetics | |
| Antibiotics | ||
| Nonsteroidal Anti-inflammatory Drugs (NSAIDs) | ||
| Immunosuppressants | ||
| Steroids | ||
| Other Applications | ||
| By Route of Administration | Oral | |
| Parenteral | ||
| Other Routes of Administration | ||
| Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Geography | Europe | Germany |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| Geography | Asia-Pacific | China |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific | ||
| Geography | Rest of the World |
Nanoemulsion Market Research FAQs
What is the current Global Nanoemulsion Market size?
The Global Nanoemulsion Market is projected to register a CAGR of 7.20% during the forecast period (2024-2029)
Who are the key players in Global Nanoemulsion Market?
Covaris Inc., Microfluidics (IDEX Corporation), Allergan PLC, Ascendia Pharmaceuticals and Owen Biosciences, Inc are the major companies operating in the Global Nanoemulsion Market.
Which is the fastest growing region in Global Nanoemulsion Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Global Nanoemulsion Market?
In 2024, the North America accounts for the largest market share in Global Nanoemulsion Market.
What years does this Global Nanoemulsion Market cover?
The report covers the Global Nanoemulsion Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Global Nanoemulsion Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Nanoemulsion Industry Report
Statistics for the 2024 Nanoemulsion market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Nanoemulsion analysis includes a market forecast outlook 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
